Q3313607 (Q3313607): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Development of a diagnostic test (ELISA) to detect antibodies against tumour antigen NY-ESO-1, translated_summary) |
||||||||||||||
Property / summary | |||||||||||||||
Development of a diagnostic test (ELISA) to detect antibodies against tumour antigen NY-ESO-1 (English) | |||||||||||||||
Property / summary: Development of a diagnostic test (ELISA) to detect antibodies against tumour antigen NY-ESO-1 (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / summary: Development of a diagnostic test (ELISA) to detect antibodies against tumour antigen NY-ESO-1 (English) / qualifier | |||||||||||||||
point in time: 25 October 2021
|
Revision as of 22:31, 24 October 2021
Project Q3313607 in Germany
Language | Label | Description | Also known as |
---|---|---|---|
English | No label defined |
Project Q3313607 in Germany |
Statements
347,150.02 Euro
0 references
433,937.52 Euro
0 references
80.0 percent
0 references
11 January 2018
0 references
30 April 2021
0 references
Adversis Pharma GmbH
0 references
Entwicklung eines diagnostischen Tests (ELISA) zum Nachweis von Antikörpern gegen das Tumorantigen NY-ESO-1 (German)
0 references
Development of a diagnostic test (ELISA) to detect antibodies against tumour antigen NY-ESO-1 (English)
25 October 2021
0 references
Leipzig, Stadt
0 references
Identifiers
672 / 101003528841
0 references